Tiny study aims to unlock why dupilumab works for eczema

NCT ID NCT05858619

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how dupilumab, an approved eczema drug, changes immune cells in the skin. Researchers will take skin samples from 15 adults with moderate-to-severe eczema before and after treatment. The goal is to understand the molecular changes that lead to improvement, not to test if the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Dupilumab

What this could lead to

If successful, this could help doctors predict which eczema patients will benefit most from dupilumab and why.

What could go wrong

This is a very small, early-phase study with only 15 participants, so results may not apply to everyone. It is designed to gather information, not to prove a new treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••